Hemophilia A treatment Adynovate (antihemophilic factor (recombinant), pegylated) has been approved for usage in Japan.
US drugmaker Baxalta (NYSE:BXLT), which is in the process of being taken over by Ireland-based pharmaceutical group Shire (LSE: SHP), has gained the approval based on positive results of a Phase III study.
Built on Advate (antihemophilic factor (recombinant)), the world's most widely used FVIII treatment for hemophilia A, Adynovate offers a twice-weekly dosing schedule. It leverages proprietary pegylation technology designed to extend the time FVIII is available in the body.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze